WASHINGTON, Oct. 31 -- The Biotechnology Industry Organization issued the following news release:
The Biotechnology Industry Organization (BIO) today announced panel sessions for the 3rd annual BIO Convention in China to be held November 11-13, 2013 in Beijing. The program will feature science-focused sessions such as vaccine development, China's unmet medical needs and the research and development of orphan drugs to treat rare diseases in China, as well as business-focused sessions exploring China's private health care industry, early-stage VC funding in China, and partnering models between Chinese and Western companies. Convention programming and exhibition will take place November 12-13.
"China has the potential to build a world-class innovative biologics sector," said Joseph Damond, senior vice president of international affairs at BIO. "This year's BIO China program helps support that ambition by bringing together western and Chinese life sciences companies as well as business leaders, government officials and other industry representatives for learning and deal-making opportunities."
Three can't miss panels include:
* Company Partnerships in Vaccine Developments in China
China and its neighboring countries represent a significant private sector opportunity for new vaccines. Chinese vaccine companies, working in partnership with other vaccine companies, are developing important medicine that addresses the specific unmet medical needs in China and other Asian markets. These collaborations bring novel vaccine technology into the Chinese research institutions while offering small and large Western vaccine companies the opportunity to bring new products to the growing Chinese private sector. Vaccines that protect against pneumococcal disease, HPV, influenza and RSV are in development or clinical trials. The panelists for this topic will discuss successful partnerships designed to solve key public health issues in China and other emerging markets.
Tuesday, November 12, 11:00 a.m. - 11:55 a.m.
Moderator: Ralf Altmeyer, PhD, Director General, Institut Pasteur of Shanghai, Chinese Academy of Sciences
Panelists: Li Shi, CEO, Shanghai Zerun Biotech; Jean-Denis Shu, MD, Medical Director, Sanofi Pasteur, China
* Rare Diseases in China
The establishment of China's first national organization against rare diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms the country's commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of orphan drugs in China.